Applications of Recombinant Adenovirus-p53 Gene Therapy for Cancers in the Clinic in China.

Abstract excerpt

Suppression of TP53 function is nearly ubiquitous in human cancers, and a significant fraction of cancers have mutations in the TP53 gene itself. Therefore, the wild-type TP53 gene has become an important target gene for transformation research of cancer gene therapy. In 2003, the first anti-tumor gene therapy drug rAd-p53 (recombinant human p53 adenovirus), trade name Gendicine™, was approved by the China Food...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Adenoviridae
• Share to China
• Share to Genetic Therapy